[go: up one dir, main page]

AR061083A1 - Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen - Google Patents

Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen

Info

Publication number
AR061083A1
AR061083A1 ARP070102020A ARP070102020A AR061083A1 AR 061083 A1 AR061083 A1 AR 061083A1 AR P070102020 A ARP070102020 A AR P070102020A AR P070102020 A ARP070102020 A AR P070102020A AR 061083 A1 AR061083 A1 AR 061083A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
heteroaryl
cycloalkyl
heterocyclyl
Prior art date
Application number
ARP070102020A
Other languages
English (en)
Inventor
Samit K Bhattacharya
Peter H Dorff
Matthew Brown
Greca Susan D La
Robert J Maguire
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR061083A1 publication Critical patent/AR061083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Se refiere a compuestos de Formula 1 y a sales farmacéuticamente aceptables, profármacos, solvatos o hidratos de los mismos. También se refiere a un método de uso de tales compuestos en el tratamiento de enfermedades hiperproliferativas y enfermedades autoinmunes de mamíferos, especialmente en seres humanos, y a composiciones farmacéuticas que contienen tales compuestos. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, en la que B se selecciona entre el grupo que consiste en fenilo y un anillo heteroarilo (de 5 a 6 miembros); D se selecciona entre el grupo que consiste en fenilo y un anillo heteroarilo (de 5 a 6 miembros); E se selecciona entre el grupo que consiste en fenilo y un anillo heteroarilo (de 5 a 6 miembros); R1 es un radical seleccionado entre el grupo que consiste en hidrogeno, alquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)-, heteroaril (C1-12)-, R7- SO2-, , R7-C(O)-, R7O-C(O)- y (R7)2N-C(O)-; donde cada uno de dichos radicales alquil (C1-6)-, alquenil C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)-, heteroaril (C1-12)-, R7-SO2-, R7-C(O)-, R7O-C(O)- y (R7)2N- C(O)-R1 puede estar opcionalmente sustituido con uno a tres restos seleccionados independientemente entre el grupo que consiste en hidrogeno, hidroxi, halogeno, -CN, alquil (C1-6)-, alcoxi (C1-6)-, perhaloalquil (C1-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)- y heteroaril (C1-12)-; cada R2 es un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, hidroxi, halogeno, -CN, alquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3- 7)-, heterociclil (C2-9)-, aril (C6-10)- y heteroaril (C1-12)-; donde cada uno de dichos radicales alquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)- y heteroaril (C1-12)- R2 puede estar opcionalmente sustituido con uno a tres restos seleccionados independientemente entre el grupo que consiste en hidrogeno, hidroxi, halogeno, -CN, alquil (C1-6)-, perhaloalquil (C1-4)-, perhaloalcoxi (C1-4)-, cicloalquil (C3-7)-, heterociclil (C2-9)- , aril (C6-10)- y heteroaril (C1-12)-; cada r3 es un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, halogeno, hidroxi, -CN, alquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, alcoxi (C1-6)-, perhaloalquil (C1-6)- y perhaloalcoxi (C1-6)-; cada R4 es un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, halogeno, hidroxi, -CN, -N(R6)2, alquil (C1-6)-, alquenil (C2-6)-, alquinil (C3-6)-, alcoxi (C1-6)-, perhaloalquil (C1-6)-, alquil (C1-6)-S(O)k-, R10C(O)N(R10)-, (R10)2NC(O)-, R10C(O)-, R10OC(O)-, (R10)2NC(O)N(R10)-, (R10)2NS(O)-, (R10)2NS(O)2-, cicloalquil (C3-7)-, aril (C6-10)-, heterociclil (C2-9)- y heteroaril (C1-12)-; donde cada uno de dichos radicales alquil (C1-6)-, alquenil (C2-6)-, alquinil (C3-6)-, alcoxi (C1-6)-, alquil (C1-6)-S(O)k-, R10C(O)N(R10)-, (R10)2NC(O)-, R10C(O)-, R10OC(O)-, (R10)2NC(O)N(R10)-, (R10)2NS(O)-, (R10)2NS(O)2-, cicloalquil(C3-7)-, aril (C6-10)-, heterociclil (C2-9)- y heteroaril (C1-12)-R4 puede estar opcionalmente sustituido con uno a cinco restos seleccionados independientemente entre el grupo que consiste en halogeno, hidroxi, -CN, alquil (C1-6)-, cicloalquil (C3-7)-, alcoxi (C1-6)- y perhaloalcoxi (C1-6)-; R5 es un radical seleccionado entre el grupo que consiste en hidrogeno, halogeno, -CN, alquil (C1-10)-, alcoxi (C1-6)-, alquenil (C2-10)-, alquinil (C2-10)-, cicloalquil (C3-7)-, aril (C6-10)-, heterociclil (C2-9)-, heteroaril (C1-12)-, cicloalquil (C3-7)-O-, aril (C6-10)-O-, heterociclil (C2-9)-O-, heteroaril (C1-12)-O-, R7-S-, R7-SO-, R7-SO2-, R7-C(O)-, R7-C(O)-O-, R7O-C(O)- y (R7)2N-C(O)-; donde cada uno de dichos radicales alquil (C1-10)-, alcoxi (C1-6)- y alquinil (C2-10)-R5 puede estar opcionalmente sustituido con uno a cinco restos seleccionados independientemente entre el grupo que consiste en halogeno, hidroxi, -CN, alquil (C1-6), cicloalquil (C3-7)-, aril (C6-10)-, alcoxi (C1-6)-, heterociclil (C2-9)- y heteroaril (C1-12)-; donde cada uno de dichos radicales cicloalquil (C3-7)- y cicloalquil (C3-7)-O-R5 puede estar opcionalmente sustituido con uno a cinco restos seleccionados independientemente entre el grupo que consiste en halogeno, hidroxi, -CN, alquil (C1- 6)-, aril (C6-10)-, alcoxi (C1-6)-, heterociclil (C2-9)- y heteroaril (C1-12)-; donde cada uno de dichos radicales aril (C6-10)-, heterociclil (C2-9)-, heteroaril (C1-12)-, aril (C6-10)-O-, heterociclil (C2-9)-O- y heteroaril (C1-12)-O-R5 puede estar opcionalmente sustituido con uno a cinco restos seleccionados independientemente entre el grupo que consiste en halogeno, hidroxi, -CN, alquil (C1-6)- y alcoxi (C1-6)-; donde cada uno de dichos radicales R7-S-, R7-SO-, R7-SO2-, R7-C(O)-, R7- C(O)-O-, R7O-C(O)- y (R7)2N-C(O)-R5 puede estar opcionalmente sustituido con uno a cinco restos seleccionados independientemente entre el grupo que consiste en halogeno, hidroxi, -CN, alquil (C1-6)-, cicloalquil (C3-7)- y alcoxi (C1-6)-; donde cada uno de los restos alquil (C1-6)-, alcoxi (C1-6)-, aril (C6-10)-, alcoxi (C1-6)-, heterociclil (C2-9)- y heteroaril (C1-12)- mencionados anteriormente para cada uno de los radicales R5 mencionados anteriormente puede estar opcionalmente sustituido con uno a cinco grupos halogeno; opcionalmente dicho radical R5 y un radical R4 o dos radicales R4 pueden tomarse junto con E para formar un anillo bicíclico condensado (de 8 a 10 miembros) que contiene opcionalmente de 1 a 4 heteroátomos seleccionados entre el grupo que consiste en O, S o N(R6); donde dicho anillo bicíclico condensado (de 8 a 10 miembros) está opcionalmente sustituido adicionalmente con uno a dos grupos oxo (=O); cada R6 en un enlace o un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, alquil (C1-6)-, -CN y perhaloalquil (C1-6)-; cada R7 es un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, -CN, alquil (C1-6)-, perhaloalquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)- y heteroaril (C1-12)-; cada R8 es un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, hidroxi, halogeno, -CN, -NH(R)), alquil (C1-6)-, perhaloalquil (C1-6)- y alcoxi (C1-6)-; donde cada uno de dichos radicales alquil (c1-6)- y alcoxi (c1-6)-R8 está opcionalmente sustituido con uno a cinco restos seleccionados entre el grupo que consiste en perhaloalquil (C1-6)-, - O(R9) y -N(R9)2; cada R9 es un radical seleccionado independientemente entre el grupo que consiste en hidrogeno, alquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)-, heteroaril (C1-12)-, R7-S- , R7-SO-, R7-SO2-, R7-C(O)-, R7-C(O)-O-, R7O-C(O)- y (R7)2N-C(O)-; donde cada uno de dichos radicales alquil (C1-6)-, alquenil (C2-6)-, alquinil (C2-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)-, heteroaril (C1-12)-R9 está opcionalmente sustituido con uno a tres restos seleccionados independientementes entre el grupo que consiste en hidrogeno, hidroxi, halogeno, -CN, alquil (C1-6)-, alcoxi (C1-6)-, perhaloalquil (C1-6)-, cicloalquil (C3-7)-, heterociclil (C2-9)-, aril (C6-10)- y heteroaril (C1-12)-; cada R10 es un radical seleccionado entre el grupo que consiste en hidrogeno y alquil (C1-6)-; k es un numero entero de 0 a 2; cada uno de m y n es independientemente un numero entero de 0 a 3; p es un numero entero de 1 a 2; q es un numero entero de 0 a 2; y cada uno de r, s, t y u es independientemente un numero entero de 0 a 4.
ARP070102020A 2006-05-09 2007-05-09 Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen AR061083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79921106P 2006-05-09 2006-05-09

Publications (1)

Publication Number Publication Date
AR061083A1 true AR061083A1 (es) 2008-08-06

Family

ID=38420744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102020A AR061083A1 (es) 2006-05-09 2007-05-09 Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen

Country Status (27)

Country Link
US (2) US7671043B2 (es)
EP (2) EP2258700A1 (es)
JP (1) JP4383525B2 (es)
KR (1) KR20090007792A (es)
CN (1) CN101490046A (es)
AR (1) AR061083A1 (es)
AU (1) AU2007251282A1 (es)
BR (1) BRPI0711358A2 (es)
CA (1) CA2651629A1 (es)
CR (1) CR10412A (es)
DO (1) DOP2007000092A (es)
EA (1) EA200802058A1 (es)
EC (1) ECSP088870A (es)
IL (1) IL194954A0 (es)
MA (1) MA30403B1 (es)
ME (1) MEP43308A (es)
MX (1) MX2008013990A (es)
NL (1) NL2000627C2 (es)
NO (1) NO20084382L (es)
PE (1) PE20080091A1 (es)
RS (1) RS20080525A (es)
TN (1) TNSN08446A1 (es)
TW (1) TW200808783A (es)
UA (1) UA91129C2 (es)
UY (1) UY30326A1 (es)
WO (1) WO2007132307A1 (es)
ZA (1) ZA200809002B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013990A (es) * 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
CN101511827B (zh) 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
CA2661315C (en) 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
CN101522645B (zh) 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
MX2009006304A (es) 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
CA2703987A1 (en) * 2007-11-08 2009-05-14 Pfizer Inc. Cyclobutyl carboxylic acid derivatives
CA2710345C (en) * 2007-12-21 2016-11-15 Merck Serono S.A. Triazole oxadiazoles derivatives
EP2262799B1 (en) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
US20110046170A1 (en) * 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
AU2009220893A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
NZ588438A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
AU2009288738B9 (en) 2008-08-27 2015-04-16 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
CA2752804C (en) * 2009-03-03 2017-04-04 Anna Quattropani Oxazole pyridine derivatives useful as s1p1 receptor agonists
EP2454255B1 (en) 2009-07-16 2013-11-06 Actelion Pharmaceuticals Ltd. Pyridin-4-yl derivatives as s1p1/edg1 agonists
TW201120016A (en) * 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
JP5869579B2 (ja) * 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
ES2544086T3 (es) 2011-01-19 2015-08-27 Actelion Pharmaceuticals Ltd. Derivados de 2-metoxi-piridin-4-ilo
EP2511275A1 (en) 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
DE102011083271A1 (de) 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
PH12017502097B1 (en) 2015-05-20 2023-05-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN109956912B (zh) * 2017-12-26 2021-10-22 中国医学科学院药物研究所 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
PT3820572T (pt) 2018-07-13 2023-11-10 Gilead Sciences Inc Inibidores pd-1/pd-l1
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
USD937488S1 (en) 2020-10-05 2021-11-30 Jonathan R. Barnes Pair of nail clipper handles

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
JPH11512750A (ja) 1996-06-27 1999-11-02 ファイザー インク． ２―（２―オキソ―エチリデン）―イミダゾリジン―４―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
WO1999017770A1 (en) 1997-10-06 1999-04-15 Basf Aktiengesellschaft Indeno[1,2-c]pyrazole derivatives for inhibiting tyrosine kinase activity
CN1280580A (zh) 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1073435B1 (en) 1998-04-30 2004-07-07 Abbott GmbH & Co. KG Substituted tricyclic pyrazole derivatives with protein kinase activity
HUP0103617A2 (hu) 1998-05-29 2002-02-28 Sugen, Inc. Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
IL141239A0 (en) 1998-08-27 2002-03-10 Pfizer Prod Inc Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
CA2344249A1 (en) 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
CN1335836A (zh) 1998-11-06 2002-02-13 巴斯福股份公司 三环吡唑衍生物
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
TR200201296T2 (tr) 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
IL146474A0 (en) 1999-06-03 2002-07-25 Knoll Gmbh Benzothiazinone and benzoxazinone compounds
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ES2298165T3 (es) 1999-11-22 2008-05-16 Smithkline Beecham Plc Derivados de imidazol.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
PT1255752E (pt) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
AU4691601A (en) * 2000-04-21 2001-11-12 Shionogi & Co Oxadiazole derivatives having anticancer effects
JP4044839B2 (ja) 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク 異常細胞増殖を治療するための置換２環式誘導体
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
SV2007000775A (es) 2001-01-05 2007-03-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP1424078A4 (en) 2001-09-04 2009-03-25 Ono Pharmaceutical Co RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
CA2476281A1 (en) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
ATE365165T1 (de) 2002-03-01 2007-07-15 Smithkline Beecham Corp Diaminopyrimidine und deren verwendung als angiogenesehemmer
US20050215531A1 (en) 2002-05-16 2005-09-29 Thomas Baumruker Use of edg receptor binding agents in cancer
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
SE0203654D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
BRPI0409097A (pt) * 2003-04-10 2006-04-11 Avanir Pharmaceuticals derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
EP2308879A1 (en) * 2004-04-02 2011-04-13 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7511062B2 (en) * 2004-05-18 2009-03-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
MX2008013990A (es) * 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
CA2703987A1 (en) * 2007-11-08 2009-05-14 Pfizer Inc. Cyclobutyl carboxylic acid derivatives
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Also Published As

Publication number Publication date
IL194954A0 (en) 2009-08-03
AU2007251282A1 (en) 2007-11-22
MA30403B1 (fr) 2009-05-04
UY30326A1 (es) 2008-01-02
EP2258700A1 (en) 2010-12-08
KR20090007792A (ko) 2009-01-20
TNSN08446A1 (en) 2010-04-14
ECSP088870A (es) 2008-12-30
WO2007132307A1 (en) 2007-11-22
ZA200809002B (en) 2009-12-30
RS20080525A (sr) 2009-09-08
MX2008013990A (es) 2009-01-29
UA91129C2 (ru) 2010-06-25
NO20084382L (no) 2008-11-19
NL2000627C2 (nl) 2009-03-17
TW200808783A (en) 2008-02-16
NL2000627A1 (nl) 2007-11-12
JP4383525B2 (ja) 2009-12-16
EP2021338A1 (en) 2009-02-11
EA200802058A1 (ru) 2009-06-30
PE20080091A1 (es) 2008-02-14
CR10412A (es) 2008-11-28
US7671043B2 (en) 2010-03-02
CN101490046A (zh) 2009-07-22
DOP2007000092A (es) 2007-12-31
CA2651629A1 (en) 2007-11-22
MEP43308A (en) 2011-02-10
US20070270438A1 (en) 2007-11-22
US20100120794A1 (en) 2010-05-13
BRPI0711358A2 (pt) 2011-09-27
JP2009536190A (ja) 2009-10-08

Similar Documents

Publication Publication Date Title
AR061083A1 (es) Derivados de cicloalquilaminoacidos y composiciones farmaceuticas que los contienen
AR059984A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR069146A1 (es) Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
AR043434A1 (es) Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos
AR060401A1 (es) Derivados de cromen-2-ona
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
AR054186A1 (es) Derivados de tetrahidroindazolona y tetrahidroindolona
AR076228A1 (es) Piperidinas sustituidas como antagonistas de ccr3
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR062731A1 (es) Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion.
AR038823A1 (es) Composiciones farmaceuticas para inhibidores de proteasa viral de la hepatitis c
AR036716A1 (es) Un compuesto derivado de bencimidazolidinona, metodos que lo utilizan, una composicion farmaceutica que lo comprende y uso de dicho compuesto o composicion
BRPI0418127A (pt) uso de um composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, método para o tratamento de infecções envolvendo vìrus da sub-famìlia pneumovirinae, formulação farmacêutica, métodos para tratar mamìferos infectados e para prevenir a infecção de mamìferos com vìrus da sub-famìlia pneumovirinae, composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, composto e a forma n-óxido e sal piridìnio do mesmo, e, método de separação de enantiÈmeros de um composto
AR079553A1 (es) Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.
AR092307A1 (es) Derivados de manosa para el tratamiento de infecciones bacterianas
AR061792A1 (es) Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa
AR081252A1 (es) Compuestos para el tratamiento del sindrome metabolico
AR061015A1 (es) Compuesto y composicion farmaceutica para el tratamiento de un trastorno del sistema nervioso central relacionado con o afectado por el receptor histamina-3 y para la inhibicion del receptor h3 y proceso para la preparacion del compuesto
AR067648A1 (es) Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen
CO2017004603A2 (es) Inhibidores de replicación del virus respiratorio inicial (rsv) derivados de 1´-[1h- 1,3-benzodiazol-2-il]metil}- espiro[ciclopropano-1,3'-indol]-2'-ona o 1´-[1h-1,3- benzodiazol-2-il]metil)espiro[ciclopropano-1,3'-pirrolo [2,3-c]piridin]'(1'h)-ona, composiciones que los comprenden y métodos de preparación

Legal Events

Date Code Title Description
FA Abandonment or withdrawal